Hemostasis and Thrombosis Flashcards

1
Q

define hemostasis

A

the arrest of blood loss from damaged blood vessles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

hemostasis is caused by

A
  • platelet adhesion and activation
  • fibrin formation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

define thrombosis

A
  • pathological formation of a hemostatis plug within the vasculature in the absence of bleeding
  • hemostasis in the wrong place
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what makes up Virchow’s triad in thrombosis

A
  • stasis
  • vessel wall injury
  • hypercoagulability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

describe white thrombus

A
  • arterial clot
  • primarily platelets and some fibrin mesh
  • associated with atherosclerosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

describe red thrombus

A
  • venous clot
  • mostly fibrin and small amount of platelets
  • higher risk of embolus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what does antithrombin III do

A

prevents coagulation by lying factor Xa and thrombin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what does thrombin (factor IIa) do

A

causes platelet activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe the intrinsic pathway

A
  • all components present in the blood
  • starts when blood comes in contact with foreign object or damaged endothelium
  • monitored by activated partial thromboplastin time (aPTT)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

describe the extrinsic pathway

A
  • some components come from outside blood: tissue factor
  • starts when tissue damage releases tissue factor
  • monitored by prothrombin time and INR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

describe vitamin K and how it is obtained

A
  • fat soluble vitamin with little stored in the body
  • most vitamin K obtained from diet or produced by bacteria in the gut
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

vitamin K is a cofactor in the formation of which clotting factors:

A
  • factor I
  • factor 7
  • factor 9
  • factor 10
  • protein C
  • protein S
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

warfarin works by inhibiting the action of:

A

vitamin K

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the platelet role in thrombus formation

A
  • platelet adhesion: following vascular damage, VWF
  • platelet activation: mediators are ADP, TXA2, collagen, thrombin -> shape change
  • platelet aggregation: final common pathway, GP IIb/IIIa receptor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the key mediator in fibrinolysis

A

plasmin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what makes plasmin

A

tissue plasminogen activator and plasminogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what does plasmin do

A

fibrin -> clot fragmentation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what are the types of anticoagulant medications

A
  • vitamin K antagonist
  • unfractionated heparin
  • low molecular weight heparins
  • direct thrombin inhibitors
  • factor Xa inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what is an example of a vitamin K antagonist and its MOA

A
  • warfarin
  • acts only in vivo
  • inhibits vitamin K epoxide reductase component 1
  • this gene is polymorphic resulting in different affinities for warfarin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what are the pharmacokinetics of wafarin

A
  • rapidly absorbed after oral administration
  • highly bound to plasma proteins
  • hepatically metabolized
  • onset of action 5-7 days
  • half life is about 40 hours
  • requires new steady state of clotting factors to be achieved
  • effects of dose change require 2-3 days to present
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what are the effects of coagulation parameters from warfarin

A
  • INR increases
  • PT increases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

warfarin exerts an ______ effect on aPTT

A

inconsistent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

warfarin is monitored using ____ and the goal is ____

A

INR; 2-3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what are the adverse drug reactions for warfarin

A
  • bleeding- can be life threatening
  • GI bleeding most common
  • rash
  • skin necrosis
  • taste disturbance
  • purple toe syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
what are the drug-drug interactions with warfarin
- drugs that change hepatic metabolism of warfarin - drugs that displace warfarin from protein binding sites - drugs that change vitamin K levels - drugs that increase the risk of bleeding
26
what are the effects of drugs that change hepatic metabolism of warfarin
- inhibition -> more effect of warfarin -> elevated INR - induction -> less effect of warfarin -> decreased INR
27
what are the effects of drugs that displace warfarin from protein binding sites
- more free drug -> more effect of warfarin -> elevated INR
28
what are the effects of drugs that change vitamin K levels
- broad spectrum antibiotics reduce GI flora -> less vitamin K and more effect of warfarin -> elevated INR - intake of vitamin K decreases effect of warfarin -> decreased INR
29
what is the use and main interactions with warfarin
- atrial fibrillation, DVT/PE tx and prevention - interactions: acetominophen - narrow therapeutic index medication
30
what are the dental implications for warfarin
- most procedures can be done without holding - for dental procedure that may result in excessive bleeding consult prescribing physician to adjust dose or hold if possible - consider local hemostasis measures to prevent excessive bleeding - check INR level prior to performing dental surgical procedure - AB use after dental procedure may increase the risk of bleeding
31
what is the MOA of heparin
- inhibits coagulation in vivo and in vitro - activation of antithrombin III - increases antithrombin III affinity for factor Xa and thrombin
32
what are the pharmacokinetics of heparin
- not absorbed from the GI tract - administered IV or SQ - fast onset: immediately after IV, 60 minutes after SQ - half life is about 40-90 minutes
33
what is heparins effect on coagulation paramaters
aPTT increases
34
heparin is monitored using ____ and the goal is _____
aPTT; 1.5-2.5 times control
35
what are the adverse drug reactions for heparin
- bleeding - thrombosis: heparin associated thrombocytopenia (HAT) and heparin induced thrombocytopenia (HIT) - osteoporosis with long term treatment - aldosterone inhibition -> hyperkalemia - hypersensitivity reaction
36
what can reverse the bleeding effects of heparin and how
protamine - binds heparin
37
what is the use, drug interactions and dental implications of heparin
- use: many including ACS, DVT/PE, atrial fibrillation - drug interactions: none significant to dentistry - dental implications: none besides bleeding
38
what is the MOA of low molecular weight heparin
- inhibits coagulation in vivo and in vitro - smaller portion of the heparin molecule - not large enough to interact with thrombin - activation of antithrombin III - increases. antithrombin III affinity for factor Xa but not thrombin
39
what are the pharmacokinetics of low molecular weight heparin
- not absorbed from the GI tract - administered SQ = fast onset and predictable response - cleared by the kidneys - half life is 4.5-7 hoursw
40
what is LMWH effect on coagulation parameters
LMWH do not require monitoring of coagulation parameters
41
what is the use, ADRs and drug interactions of LMWH
- use: many including ACS, DVT/PE, atrial fib - ADRs: bleeding, thrombosis, osteoporosis, hyperkalemia, hypersensitivity - lower incidence of HIT than unfractionated heparin - drug interactions: increased risk of bleeding with NSAIDs and aspirin
42
what are the dental implications of LMWH
- determine why pt is taking medication = delay proceudre until tx complete - do not discontinue therapy - consider local hemostasis to prevent excessive bleeding
43
what is the MOA for direct thrombin inhibitors
- derived for the saliva of medicinal leeches - binds to the fibrin binding sites of thrombin preventing the conversion of fibrinogen to fibrin
44
what are the pharmacokinetics of direct thrombin inhibitors
- IV agents: argatroban and bivalirudin - oral agent: dabigatran
45
what are the direct thrombin inhibitors effect on coagulation parameters
- argatroban has a drug-lab interaction resulting in falsely elevated INR - dabigatran does not require monitoring of coagulation tests - argatroban and bivalirudin may be monitored by aPTT depending on indication
46
what is the brand name, use, ADRs, drug inreactions, dental implications of direct thrombin inhibitors
- pradaxa - use: atrial fibrillation, DVT/PE treatment and prevention - ADRs: bleeding, dyspepsia/gastrisis (25-35%) - drug interactions: incresed risk of bleeding with NSAIDs and aspirin - dental implications: high risk of bleeding, high risk of thrombosis if stopped- short half life
47
what drug reverses direct thrombin inhibitors for bleeding issues and what is the downside of it
- idarucizumab - reversal costs $5,000
48
what is the MOA of factor Xa inhibitors
- binds to factor Xa and prevents the conversion of prothrombin to thrombin
49
what are the pharmacokinetics of factor Xa inhibitors
- parenteral agent: fondaparinux (SQ) - oral agents: apixaban, edoxaban, rivaroxaban
50
what are the factor Xa inhibitor effects on coagulation parameters
- factor Xa inhibitors have an inconsistent effect on coagulation tests - factor Xa inhibitors do not require monitoring, do require renal dosing
51
what is the brand name, use, ADRs, drug interactions and dental implications of factor Xa inhibitors
- eliquis - use: atrial fibrillation and DVT/PE treatment and prevention - ADRs: bleeding - drug interactions: increases risk of bleeding with NSAIDs and aspirin - dental implications: high risk of bleeding, high risk of thrombosis if stopped - short half life
52
what is the reversal agent for factor Xa inhibitors and what is the downside of it
- andexanet alfa - $25,000-$30,000
53
non vitamin K oral anticoagulants is an overarching term referring to:
- apixaban - dabigatran - edoxaban - rivaroxaban
54
NOACs are recommended over warfarin for:
prevention of stroke and systemic embolism AF and DVT/PE treatment due to ease of use
55
what is another name for NOACs
direct acting oral anticoagulants
56
what is the coagulation cascade of the intrinsic pathway
- factor 12 -> factor 11 -> factor 10 -> factor Xa
57
what is the extrinsic pathway coagualtion cascade
factor 7 + tissue factor -> factor 7a -> factor Xa
58
what are the antiplatelet medications
- COX inhibitor - P2Y12 inhibitors - glycoprotein IIb/IIa inhibitors - PAR-1 antagonist
59
what is the MOA of aspirin
- inhibits cyclo oxygenase 1 - prevents formation of prostaglandin which is converted to thromboxane A2 - low dose ASA (81mg) inhibits more than 95% of platelet TXA2 formation - platelets can not make new COX-1 ASA effects last for life of platelet 7-10 days
60
what are the more common and less common adverse reactions from aspirin
- more common: bleeding (GI), GI distress, rash - less common: angioedema, tinnitus, respiratory distress
61
what is the use, and drug interactions of aspirin
- use: many including secondary prevention of coronary disease, arthritis, anti-inflammatory - drug interactions: increased risk of bleeding with NSAIDS and other anticoagulants. may lower the effectiveness of anti hypertensive agents
62
what are the dental implictions of aspirin
- determine why it is being taken - most procedures can be done without holding aspirin - increased risk of bleeding - consider local hemostatis mesure to prevent excessive bleeding
63
what is the MOA of P2Y12 inhibitors
inhibition of ADP binding to the P2Y12 receptor
64
what is the metabolism of P2Y12 inhibitors
- clopidogrel: CYP 2C19 - prasugrel: CYP 2C19
65
what are the ADRs of P2Y12 inhibitors
- bleeding: less occurence than aspirin when used as a monotherapy, increased ocurrence when used with aspriin - skin rash (10%) - thrombocytopenia (rare) - ADRs unique to tricagrelor: dyspnea and elevated serum creatinine
66
what are the drug interactions of P2Y12 inhibtors
- mainly due to CYP 450 inhibition - prodrugs require activation by CYP 450 therefore have less activity resulting in increased risk of thrombotic event - tricagrelor active upon administered therefore inhibition results in increased levels and activity leading to increased risk of bleeding - all P2Y12 inhibitors interact with other medciations that increase risk of bleeding
67
what is the use of P2Y12 inhibitors
treatment of acute coronary syndrome
68
what are the dental implications of P2Y12 inhibitos
- plan for increased bleeding - do not stop without consulting prescribing physician - do not alter aspirin prescribed dose - ticagrelor specific
69
what is the mechanism of action of glycoprotein IIb/IIIa inhibitors
- bind to GP IIa/IIIa receptor preventing platelet aggregation - only available IV - eptifibatide and tirofiban
70
what is the example, use, ADRs, drug interactions and dental implications of glycoprotein IIb/IIIa inhibitors
- eptifibatide - use: treatment of acute coronary syndrome - ADRs: bleeding (highest of all antiplatelet agents), thrombocytopenia - drug interactions: none significant to dentistry - dental implications: none
71
what is the MOA of PAR-1 antagonist
- antagonist of the protease activated receptor 1 inhibiting thrombin receptor agonist peptide (TRAP) induced platelet aggregation - does NOT effect the conversion of fibrinogen to fibrin by thrombin
72
what is the brand name, use, ADRs, drug interactions and dental implications of PAR-1 antagonist
- brand name: Zontivity - use: secondary prevention of coronary artery disease - ADRs; bleeding (25%) - drug interactions: other drugs that increase bleeding - dental implications: high bleeding risk
73
should warfarin or antiplatelet medications be alterred before dental procedures
no
74
in patients with comorbid medical conditions that can increase the risk of prolonged bleeding after dental treatment:
consult with patients physician
75
what are the fibrinolytic and antifibrinolytic medications
- fibrinolytic therapy: plasminogen activators - antifribinolytic therapy: hemostatic agents
76
what is the MOA of plasminogen activators
- binds to tissue bound fibrin and plasminogen converting plasminogen to plasmin - recombinant form of tissue plasminogen activator (TPA)
77
what is the example, use, ADRs, drug interactions and dental implications of plasminogen activators
- tenecteplase - use: STEMI, stroke - ADRs; bleeding from any site - drug interactions: none significant to dentisry - other drugs that increase bleeding - dental implications: none
78
what is the MOA of hemostatic agents
- competitve inhibition of plasmin activation by binding to plasminogen - at higher concentrations non competitive inhibition of plasmin
79
what is the example, use, ADRs, drug interactions of hemostatic agents
- tranexamic acid - use: prohylaxis of bleeding in patients at high risk of bleeding during dental procedures of surgery - ADRs: IV- hypotension and giddiness; PO- headache, abdominal pain and nasal/sinus symptoms - drug interactions: reduced the effectiveness of anticoagulants, increased risk of thrombosis
80
what are the dental implications of hemostatic agents
- used as an antifibrinolytic mouthwash following dental surgery to prevent hemorrhage in patients taking oral anticoagulants - topical administration should have limited systemic effects. if sysemic adminsitration considered consult with physician prescribing anticoagulant
81